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Introduction 
 
Cardiovascular disease is the leading cause of morbidity and mortality in patients with end-
stage renal failure. Several studies have confirmed that the incidence of atrial and ventricular 
arrhythmias is higher during hemodialysis [1-3]. Atrial fibrillation is one of the most 
commonly encountered arrhythmias in patients on chronic renal replacement therapy, with an 
incidence of approximately 10%. Independent risk factors for atrial fibrillation include age, 
gender, hypertension, diabetes mellitus, heart failure, and valvular heart disease. In patients 
with renal diseases, mortality caused by atrial fibrillation is primarily connected with 
thromboembolic consequences [4]. In addition, the hemodynamic deterioration caused by the 
arrhythmia leads to increased mortality rates, especially in patients with altered left 
ventricular systolic function [5,6]. In patients with paroxysmal atrial fibrillation during sinus 
rhythm, the intra- and interatrial conduction time of the sinus impulse lengthens, and the 
duration of the P wave measured on a surface electrocardiogram (ECG) is increased [7-12]. 
Furthermore, hemodialysis may lengthen P wave duration and dispersion [13]. Whereas 
conventional hemodialysis (HD) eliminates uremic toxins by diffusion depending on their 
molecular weights, hemodiafiltration (HDF) also eliminates toxic polypeptides (characterized 
by β-2 microglobulins) by convective transport [7,14]. The quality of life of patients 
undergoing HDF is superior to that of patients undergoing HD, and mortality rates in the 
former group are lower [8,15]. However, the effects of HDF on atrial arrhythmias are not well 
established, and the extent to which changes in arrhythmia substrates are responsible for the 
beneficial clinical results of HDF is still unknown. In the current study, we investigated the 
effects of HD and HDF on P wave duration and dispersion, two characteristics that 
characterize atrial arrhythmogenicity and are measured by a surface ECG.  
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Materials and methods 
The studied population consisted of thirty patients (18 males, 12 females, mean age 
60.57±13.62 years, range 23-85 years). First, we collected and analyzed data from the patients 
while they were undergoing HDF over a period of three months; the same patients were then 
treated with conventional HD for at least another three months, and another set of data was 
collected. Patients with end-stage kidney disease (Stage 5) participating in renal replacement 
programs in our clinic were enrolled in the study. The patients did not have impulse 
generation and/or conduction disorders, autonomic nervous system diseases, diabetes 
mellitus, Parkinson’s disease, amyloidosis, or sarcoidosis. Moreover, patients on medication 
that may have affected atrial and ventricular depolarization and repolarization (e.g., 
haloperidol, methadone, amiodarone, sotalol, selective serotonin reuptake inhibitors, 
macrolide antibiotics, antifungal agents) were excluded from our investigation. Likewise, 
because thyroid dysfunction and altered calcium metabolism may affect atrial pulse 
conduction, patients suffering from these endocrine disorders were excluded from the study. 
None of our patients had a history of atrial fibrillation. The causes of chronic renal failure in 
this patient population were the following: chronic glomerulonephritis (n=5), hypertensive 
and vascular nephropathy (n=12), chronic pyelonephritis (n=1), polycystic kidney disease 
(n=2), analgesic nephropathy (n=3), renal agenesis (n=1), lupus nephritis (n=2), and vasculitis 
(n=4). Clinical data from the study population are shown in Table 1. All patients gave 
informed consent to participate in the study, and the Institutional Ethics Committee on Human 
Research approved the study protocol. The renal replacement therapies were performed three 
times a week during 4-hour long sessions with Fresenius 4008 S and H machines (Fresenius 
Medical Care, Bad Homburg, Germany) and with Fx60 and Fx80 high-flux polysulfone 
dialyzers (Fresenius). During HDF, 15.16±5 liters of ultrafiltrate was removed using a post-
dilution technique. The replacement solution was manufactured on-line from ultrapure water 
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and consisted of 138 mmol/L sodium, 2 or 3 mmol/L potassium (in 13 cases, 2 mmol/l; in 17 
cases, 3 mmol/l), 1.5 mmol/L calcium, 0.5 mmol/L magnesium, and 1 g/L glucose. During 
HDF, the blood flow was 338±11.6 ml/min, which was not significantly different from that 
observed during HD (p<0.05). The bicarbonate dialysis solution contained the same ionic 
concentrations. We adjusted the dialysate bicarbonate concentration individually in each case 
in the range of 28-36 mmol/L for aiming at plasma bicarbonate concentration of 20-22 
mmol/L. Dialysate bicarbonate concentration was not changed during the study. No drugs 
were administered during the sessions. The serum electrolyte levels were measured four times 
during the sessions and 2 hours afterwards. ECGs were performed five times in each case: at 
the beginning of the session, 15, 30, and 240 minutes into the session, and  two hours after the 
end of the session. Electrocardiograms were recorded at a speed of 25 mm/sec (Hewlett 
Packard Page Writer 200i) while the patients were in the supine position breathing freely. 
Copies of the recordings were magnified by a factor of three. To avoid inter-observer 
variability, ECG parameters were measured by one examiner with calipers in a blinded 
fashion (with no information about the source of the ECG recording). The P wave duration 
was defined as the section beginning at the first sign of electrical activity after the T wave (or 
in some cases, the U-wave) and ending at the intersection of the P wave’s descending branch 
and the isoelectric line. Three consecutive P waves were analyzed in every lead, and their 
average duration was calculated; the resulting value was designated the P wave duration in the 
given lead. In the statistical analysis, the longest P wave of the 12 leads was used as the P 
interval (Pmax). P dispersion (Pd) was determined as the difference between the longest and 
shortest P interval. Pmax and Pd were corrected to the heart rate (Pmaxc, Pdc) according to 
Bazett’s formula (Pmaxc = Pmax/√RR (msec), Pdc= Pd/√RR (msec)). Holter-ECGs (GE 
Medical SEER Light) were performed, with monitoring starting before the therapy and ending 
24 hours afterwards. The number of supraventricular premature beats was compared to the 
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total number of beats, and the resulting modulus was used to eliminate the variations arising 
from the short differences between the duration of the examinations. Before and after the 
renal replacement therapies, a transthoracic echocardiography (M-mode, 2 D) was performed 
with pulsed and continuous wave and tissue Doppler technique (Philips ATL HDI 5000 
imaging system with a 3.5 MHz transducer). During the examinations, the cross diameter of 
the left atrium, the thickness of the septal and the posterior wall, and the left ventricular 
systolic and diastolic diameters were measured from the parasternal long-axis view. Based on 
the apical four-chamber view, Simpson’s method was used to determine the left ventricular 
ejection fraction. Statistical analysis of the data was carried out with SAS 8.2 for Windows. 
The variations in the investigated parameters over time and the differences between the two 
treatment modalities were determined using analysis of variance (ANOVA). The correlations 
between the parameters were analyzed by Pearson test when the distribution was normal and 
by Spearman’s rank test in the case of abnormal distribution. Throughout the analysis, the 
p<0.05 probability level was considered to be statistically significant. 
 
Results  
 
Pmax and Pmaxc were significantly longer during HDF than during HD, even at the 
beginning of the sessions (Pmax 102 msec vs. 88.66 msec, p=0.0036; Pmaxc 114.83 msec vs. 
99.4 msec, p=0.0036). Nevertheless, these parameters were found to be within the physiologic 
range. All investigated ECG parameters were significantly increased (p<0.05) during HD, 
whereas no significant changes were observed during HDF. Pmax, Pd, Pmaxc, and Pdc were 
significantly prolonged 30 minutes into the HD. The mean value of Pmax was 88.6 msec at 
the beginning of the HD; this value increased to 102 msec within 30 minutes (p<0.05) and 
reached its maximum value (111 msec (p<0.05)) 240 minutes into the session; Pmax then 
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decreased to 98 msec 2 hours after the end of the HD. The Pd was 37.3 msec before HD and 
52 msec within the first half hour of the session (p<0.05). Pmaxc lengthened from a 99.4 
msec baseline value to 115.5 msec and remained at that level until two hours after the 
treatment (115.3 msec). Pdc did not change in the first half hour of HD (44 msec); however, it 
decreased to 40.4 msec (p<0.05) 30 minutes into the treatment and increased to 48 msec by 
the end of the sessions (p<0.05). Two hours later, the Pdc was found to have reverted to its 
baseline value (43.9 msec). In contrast, the P wave parameters did not change significantly 
during HDF (Figures 1/a. and 1/b.). Total calcium and ionized calcium levels significantly 
increased, whereas potassium, magnesium, and phosphate levels decreased during both 
modalities. During HDF, serum sodium levels did not change significantly; however, after 15 
and 30 minutes of HD, sodium levels decreased (p<0.05) relative to baseline levels and 
increased by the end of the sessions (Table 2.). During the different treatment modalities 
praedialytic serum bicarbonate values were also determined. However, regarding these 
parameters no significant differences were evaluated (HD: 19.6±2.1 vs. HDF: 20.7±2.8; 
p=0.14). We investigated whether the praedialytic bicarbonate levels correlate with the duration 
of P interval and Pd or not. According to our data there is a significant negative correlation 
between praedilalytic bicarbonate levels and Pmax, Pd, Pdc by the end of the sessions (Table 
3.). During HDF, the change in sodium levels was significantly positively correlated with 
both Pd and Pdc. Moreover, during conventional HD, the change in ionized calcium levels 
was positively correlated with both Pd and Pdc (Table 3.). No additional significant 
correlations between the studied ECG markers and ionic parameters were found. Changes in 
the ventricular rate (characterized by the RR cycle length) increased from 798±102.65 msec 
to 852±104.3 msec (p=0.0047) after 30 minutes of HDF, indicating a transient decrease in the 
heart rate; the ventricular rate gradually decreased to its baseline rate after the sessions ended. 
With HD, the RR cycle length decreased significantly relative to the baseline length 
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(800.6±96.2 vs. 746.6±125.5 msec, p=0.024) only 2 hours after the end of the sessions. At the 
beginning of the sessions, there were no significant differences in left atrial diameter between 
the two treatment modalities; however, by the end of the sessions, a significant decrease was 
observed in the case of HDF (p=0.00017). In contrast, no significant changes in left atrial 
diameter were found during HD (p=0.12) (Figure 2.). No significant difference in atrial 
diameter between men and women was observed (p=0.56). The ratio between the baseline left 
atrial diameter and the number of supraventricular premature beats was also determined. With 
HDF, the left atrial cross diameter measured at the beginning of the sessions was positively 
correlated with the incidence of supraventricular premature beats (r=0.4556, p=0.011) 
(Figure 3/a.). Furthermore, the decrease in the left atrial diameter was negatively correlated 
with the incidence of supraventricular premature beats (r=-0.43, p=0.016) during HDF 
(Figure 3/b.). The body weight and the body mass index (BMI) of the patients decreased 
significantly during both modalities (BMI HD: 24.39±4.19 kg/m2 to 23.59±4.2 kg/m2; BMI 
HDF: 24.37±4.12 kg/m2 to 23.6±4.14 kg/m2). Importantly, the difference between the volume 
removals did not prove to be significant (p= 0.34). Atrial fibrillation did not occur during any 
of the renal replacement therapies; however, the frequency of supraventricular premature 
beats was high in both treatment modalities (HD: 363 beats/24 h; HDF: 350 beats/24 h). 
Although the Holter ECG recordings of the hemodialyzed patients showed a more frequent 
occurrence of supraventricular premature beats, the difference in the frequency of these beats 
for the two modalities was not statistically significant (p=0.14). In both treatment modalities, 
there was a rapid decrease in blood pressure to levels comparable to baseline values after the 
start of the sessions; within 15 minutes of treatment, the levels significantly decreased. The 
systolic blood pressure did not change significantly after this; however, the diastolic values 
increased after the treatments. During HDF, the systolic and diastolic values were higher even 
during the initial stages of the sessions (Figures 4/a. and 4/b.). The end systolic and diastolic 
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left ventricular diameters, the left ventricular mass index, and the left ventricular ejection 
fraction were not significantly different or altered in either of the treatments (Table 4.). 
 
Discussion 
 
The structural and electrophysiological heterogeneity of the atrial myocardium may result in 
inhomogeneous atrial depolarization and/or repolarization and unidirectional conduction 
block. These abnormalities play an important role in creating atrial premature beats and 
reentry, an electrophysiological prelude to atrial fibrillation. The duration and dispersion of 
the P wave have been shown to be prolonged in patients with paroxysmal atrial fibrillation 
during sinus rhythm [10-12]. Recent studies have also reported that the mortality rate of 
patients participating in HDF programs is 35% lower than that of patients receiving 
conventional treatment [7,8,14]. This phenomenon may be the result of the more effective 
removal of small- and medium-molecular weight substances during HDF, which might be 
related to high-flux membranes and a more appropriate convective volume [16]. The 
concentrations of acute phase proteins and inflammatory mediators do not rise during or after 
HDF. The reduction in beta-2 microglobulin concentrations achieved with HDF can reduce 
the incidence of amyloidosis by approximately 50% [17-21]. In addition to these known 
factors, it could also be hypothesized that patients receiving convective treatment for their 
renal diseases may benefit from a reduction in the incidence of arrhythmias and from the 
slower progression of damage to the heart [22,23]. Previously, we have demonstrated the 
beneficial effects of hemodiafiltration on ventricular repolarization, but the possible 
influence of this treatment modality on atrial rhythm disturbances has remained to be 
elucidated [24]. To clarify this hypothetical relationship between convective treatment and 
atrial arrhythmogeneity we decided to investigate atrial electrocardiographic arrhythmia 
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markers during hemodiafiltration and hemodialysis. Our present results show that the 
electrocardiographic changes observed during conventional HD were not observed during 
HDF. However, the reasons for the differences in Pmax and Pmaxc during the different 
modalities are not well understood, and further investigations are needed to understand this 
phenomenon. Importantly, no significant differences in the effective volume removals 
between the two treatment modalities were observed. The larger decrease in left atrial 
diameter indicates a more effective intracardiac volume, which decreases the potential of 
HDF to contribute to a considerable reduction in atrial wall stress during the convective 
treatment. Consequently, the amplified decrease in atrial volume can result in a lower 
incidence of supraventricular premature beats. Our data obtained from the 24-hour Holter 
ECG recordings show that supraventricular premature beats appeared often in both 
treatments, even though atrial fibrillation was not observed during either modality. Although, 
supraventricular premature beats were more frequent during HD, the difference in the number 
of these beats between the two treatment modalities in our study population was not 
statistically significant. The altered behavior of the ventricular frequency (characterized by 
RR cycle length) could be the result of the differences in intravascular and intracardiac 
dynamics of volume and pressure conditions resulting from HD and HDF. The changes in 
blood pressure can also highlight the role of volume and pressure load alterations. However, 
the systolic and diastolic values of the patients were higher during HDF, even at the beginning 
of the sessions, which may have affected our results. Because no significant differences in 
serum potassium, magnesium, and phosphate levels were observed between the two 
modalities, we conclude that the altered electrocardiographic activity during the different 
renal replacement therapies is not likely to be caused by the changes in these electrolyte 
levels. The significant correlations between serum sodium levels and Pd and Pdc observed 
during HDF and the correlations between the serum ionized calcium levels and Pd and Pdc 
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observed during HD indicate that these changes in electrolyte concentrations must play an 
important role in atrial arrhythmogenesis. Moreover, we found that the praedialytic 
bicarbonate levels may affect atrial arrhythmogeneity. Most importantly, our results also 
suggest that the alterations in these atrial arrhythmia markers may be the result of the 
simultaneous occurrence of certain electrolyte imbalances and renal replacement methods. 
Accordingly, we emphasize the need for and potential benefit of careful monitoring and 
control of these electrolytes during the sessions to prevent electrocardiographic changes and 
lower the risk of atrial arrhythmias. 
 
Conclusion 
Our data suggest that the electrocardiographic markers of atrial depolarization and 
repolarization do not change significantly during HDF. This finding might be the result of the 
more balanced but increased intracardiac and intravascular volume reduction, the more 
effective balancing of sodium serum concentrations, the already proven powerful 
antioxidant/anti-inflammatory effect of HDF, and the more efficient removal of the small- and 
medium-molecular weight substances and uremic toxins during HDF. Further studies are 
needed to analyze the impact of HDF on atrial arrhythmias. 
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Figure Legends 
Figures 1/a. and 1/b. Changes in P interval (Pmax) and corrected P interval (Pmaxc), P 
dispersion (Pd), and corrected P dispersion (Pdc) during hemodialysis (HD) and 
hemodiafiltration (HDF) (*p<0.05). All investigated parameters significantly increased during 
HD. No such changes were observed during HDF. 
Figure 2. Changes in left atrial diameter during hemodiafiltration (HDF) and hemodialysis 
(HD). The left atrial diameter decreased significantly during HDF. (*p<0.05)  
Figure 3/a. The correlation between the left atrial cross diameter (DLA), as measured at the 
beginning of the hemodiafiltration (HDF), and the rate of supraventricular premature beats 
(SVPB). The DLA measured at the beginning of the sessions was positively correlated with 
the incidence of supraventricular premature beats. (*p< 0.05) 
Figure 3/b. Correlation between the changes in the left atrial diameter (∆DLA) and the rate of 
supraventricular premature beats (SVPB) during hemodiafiltration (HDF). The decrease in 
left atrial diameter was negatively correlated with the incidence of supraventricular premature 
beats during HDF. (*p< 0.05) 
Figure 4/a. Changes in systolic blood pressure during the different methods of renal 
replacement therapy (*p<0.05). In both treatment modalities, systolic blood pressure rapidly 
decreased after the start of the sessions and became significantly different from the baseline 
level within 15 minutes. 
HD: hemodialysis, HDF: hemodiafiltration, BP: blood pressure, sys: systolic 
Figure 4/b. Changes in diastolic blood pressure during the different methods of renal 
replacement therapy (*p<0.05). The diastolic blood pressure rapidly decreased after the start 
of the sessions in both treatment modalities and became significantly different from the 
baseline level within 15 minutes. The diastolic pressure increased after the treatments. 
HD: hemodialysis, HDF: hemodiafiltration, BP: blood pressure, dia: diastolic 
